Pfizer Inc. (PFE) on Tuesday announced positive topline results from the Phase 2b VESPER-3 study evaluating monthly maintenance dosing of its ultra-long-acting, injectable GLP-1 receptor agonist PF'3944 in adults with obesity or overweight without type 2 diabetes. The study's dual objectives were...
Danish drug maker Novo Nordisk A/S (NVO, NOVOB.CO, NOV.DE) announced late Monday headline results from REIMAGINE 2 trial, in which CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in adults with type 2 diabetes. CagriSema is...
Venglustat
Sanofi (SNY, SAN.PA) reported that the LEAP2MONO phase 3 study demonstrated that venglustat met the primary and three out of four key secondary endpoints in adults and pediatric patients with neurological manifestations of type 3 Gaucher disease. Venglustat demonstrated superiority versus enzyme replacement...
Kazia Therapeutics Limited (KZIA) on Tuesday reported promising results from an ongoing Phase 1b study evaluating its lead drug candidate, paxalisib, in combination with pembrolizumab and chemotherapy for patients with late-stage, metastatic triple-negative breast cancer (TNBC). Three patients treated...
Bausch Health Companies Inc. (BHC.TO) on Friday said its Phase 3 RED-C clinical program evaluating amorphous rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis for the primary prevention of hepatic encephalopathy (HE) did not meet its primary endpoint. The RED-C program includes...
Moderna, Inc. (MRNA) and Merck & Co Inc. (MRK) on Tuesday reported median five-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene, an investigational personalized cancer vaccine, in combination with Merck's Keytruda in patients with high-risk melanoma...
Japan's Nxera Pharma Co., Ltd. (SOLTF) announced Monday positive top-line results from a Phase 3 study conducted in South Korea evaluating daridorexant 50 mg in adult and elderly patients with insomnia. The company said it plans to submit a marketing authorization application for daridorexant in South...
Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002. The study, conducted in healthy volunteers, evaluated the safety and pharmacokinetics of the drug. Interim results showed a half-life of 75-80 days, supporting the potential for twice-per-year...
Eli Lilly and Company (LLY) announced positive topline results from the TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. At...
Eupraxia Pharmaceuticals Inc. (EPRX), Thursday announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. The company said that the findings provide compelling evidence supporting...
Monte Rosa Therapeutics, Inc. (GLUE) announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. "In this interim data readout, after 4...
Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as first-line treatment for adults with HER2-positive locally advanced or metastatic...
NovaBridge Biosciences (NBP) on Tuesday reported positive updated results from its Phase 1b combination study of givastomig with nivolumab and chemotherapy in patients with HER2-negative, first-line metastatic gastric cancer. Givastomig continued to show robust efficacy, with overall response rates...
Johnson & Johnson (JNJ) on Tuesday reported positive topline results from the Phase 2b JASMINE study of nipocalimab in adults with systemic lupus erythematosus (SLE). The study met its primary endpoint, with a statistically significant proportion of patients achieving the SLE Responder Index (SRI-4)...
January 30, 2026 15:51 ET The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.